Acceptance testing thermal vacuum contingency plan qual SA, flight 1 & 2

Thermal vacuum watchkeeping guidelinesprepared by D. Douthat, R. Wallace.Rev

March engineering model test progress report : 31 March 1967

This is the fifth monthly progress report on the ALSEP Engineering Model Systems Tests which covers the efforts during the time period 1 March through 31 March.prepared by A. Bedford, D. Douthat, R. Gilson

Going with the flow: the supply and demand of sediment retention ecosystem services for the reservoirs in Puerto Rico

Impounding surface waters in reservoirs is a major mechanism for providing water for human consumption, including potable water, hydroelectric power, and industrial uses. Building reservoirs incurs environmental and social costs, and therefore safeguarding their effectiveness and longevity is a concern of clear public interest. One factor that affects the longevity of reservoirs is sedimentation, a process exacerbated by land use conversion in upstream watershed areas. Despite the economic importance of preventing sedimentation in existing reservoirs, few consumers are aware of the natural features that provide sediment retention services and the relevance of their conservation in their daily lives. Moreover, managing for landscape level sediment retention services is challenging due to a lack of clarity regarding supply and demand flows that transcend watershed boundaries and jurisdictions. Our study seeks to bridge these gaps by characterizing the flow of sediment retention services to reservoirs and link these services to the specific consumers that benefit using a socio-ecological network (SEN) framing. We conducted this study on the island of Puerto Rico (PR), the population of which is heavily reliant on reservoirs as a primary water resource, while experiencing severe and chronic reservoir sedimentation problems. Our study models avoided sediment export, and the costs were averted thanks to this service. We characterized protection as opposed to vulnerability of these sediment retention services by estimating the proportion of natural areas under some form of legal conservation status and the level of landscape fragmentation. We frame these services as an SEN by using water distribution lines as links to estimate the number of beneficiaries and their location relative to the reservoir’s water source. Our results identify watersheds with conservation needs, their beneficiaries, and where within those watersheds to prioritize conservation efforts to safeguard access to clean water in PR. More broadly, our study provides a model case study for establishing supply and demand service flows of water purification services and demonstrating the utility of mapping socio-ecological networks of service flows in order to justify conservation policies based on ecosystem services

Late Spectral Evolution of SN 1987A: I. Temperature and Ionization

The temperature and ionization of SN 1987A is modeled between 200 and 2000 days in its nebular phase, using a time-dependent model. We include all important elements, as well as the primary composition zones in the supernova. The energy input is provided by radioactive decay of Co-56, Co-57, and Ti-44. The thermalization of the resulting gamma-rays and positrons is calculated by solving the Spencer-Fano equation. Both the ionization and the individual level populations are calculated time-dependently. Adiabatic cooling is included in the energy equation. Charge transfer is important for determining the ionization and is included with available and estimated rates. Full, multilevel atoms are used for the observationally important ions. As input models to the calculations we use explosion models for SN 1987A calculated by Woosley et al and Nomoto et al. The most important result in this paper refers to the evolution of the temperature and ionization of the various abundance zones. The metal-rich core undergoes a thermal instability, often referred to as the IR-catastrophe, at 600 - 1000 days. The hydrogen-rich zones evolve adiabatically after 500 - 800 days, while in the helium region both adiabatic cooling and line cooling are of equal importance after ~1000 days. Freeze-out of the recombination is important in the hydrogen and helium zones. Concomitant with the IR-catastrophe, the bulk of the emission shifts from optical and near-IR lines to the mid- and far-IR. After the IR-catastrophe, the cooling is mainly due to far-IR lines and adiabatic expansion. Dust cooling is likely to be important in the zones where dust forms. We find that the dust condensation temperatures occur later than ~500 days in the oxygen-rich zones, and the most favorable zone for dust condensation is the iron core.Comment: 53 pages, including 10 figures; ApJ (Main Journal); scheduled for April 1, 1998, Vol. 49

Micromechanical Properties of Injection-Molded Starch–Wood Particle Composites

The micromechanical properties of injection molded starch–wood particle composites were investigated as a function of particle content and humidity conditions. The composite materials were characterized by scanning electron microscopy and X-ray diffraction methods. The microhardness of the composites was shown to increase notably with the concentration of the wood particles. In addition,creep behavior under the indenter and temperature dependence were evaluated in terms of the independent contribution of the starch matrix and the wood microparticles to the hardness value. The influence of drying time on the density and weight uptake of the injection-molded composites was highlighted. The results revealed the role of the mechanism of water evaporation, showing that the dependence of water uptake and temperature was greater for the starch–wood composites than for the pure starch sample. Experiments performed during the drying process at 70°C indicated that the wood in the starch composites did not prevent water loss from the samples.Peer reviewe

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease